Hangzhou Tigermed Consulting CoFRA:5HZ1 +5.41%86 ROE % is 0.95% as of Mar. 2026, which is 92% below its 10-year median of 12.66. GuruFocus rates FRA:5HZ1 with a GF Score™ of 86/100 and a GF Value™ of €5.04 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks better than 61.88% on this metric.
FRA:5HZ1'
s ROE % Range Over the Past 10 Years
Min: 1.94 Med: 12.66 Max: 23.83
Current: 3.71
During the past 13 years, Hangzhou Tigermed Consulting Co's highest ROE % was 23.83%. The lowest was 1.94%. And the median was 12.66%.
FRA:5HZ1's ROE % is ranked better than 61.88% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.31
vs FRA:5HZ1: 3.71
Hangzhou Tigermed Consulting Co (FRA:5HZ1) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Hangzhou Tigermed Consulting Co ROE % Related Terms
Hangzhou Tigermed Consulting Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's ROE % distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a ROE % of 0.95% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is 92% below median its historical median of 12.66. Over the past decade, Hangzhou Tigermed Consulting Co's ROE % has ranged from 1.94 to 23.83. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #77 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 38.1%.
Is Hangzhou Tigermed Consulting Co's ROE % too high?
Hangzhou Tigermed Consulting Co's current ROE % of 0.95% is 92% below median its 10-year median of 12.66. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 23.83. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #77 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #77 out of 202 companies for ROE %. This puts Hangzhou Tigermed Consulting Co in the upper half of its industry. Historically, Hangzhou Tigermed Consulting Co's own ROE % has ranged from 1.94 to 23.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Hangzhou Tigermed Consulting Co and its competitors. Hangzhou Tigermed Consulting Co's current ROE % is 0.95%, which is 92% below median its own 10-year median of 12.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.04, compared to a current price of €3.90 — trading 22.6% below its estimated fair value. The current ROE % is 0.95%, which is 92% below median its 10-year median of 12.66. Hangzhou Tigermed Consulting Co's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current ROE % is 0.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €3.90 is trading 22.6% below its estimated GF Value™ of €5.04.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for FRA:5HZ1:
ROE %: 0.95% (92% below median its 10-year median of 12.66)
GF Value™: €5.04 vs. price of €3.90 (22.6% below fair value)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Business Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
86GF Score
Get the complete analysis for FRA:5HZ1
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
